Cargando…
Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is a common and incurable B-cell malignancy. Recent therapeutic approaches that target the B-cell receptor signaling pathway include inhibition of phosphatidylinositol-3-kinase (PI3K). The PI3K isoform delta is constitutively active in CLL, making it an attractive...
Autores principales: | Faehling, Sebastian, Coelho, Mariana, Floerchinger, Alessia, Schneider, Christof, Stilgenbauer, Stephan, Lichter, Peter, Seiffert, Martina, Roessner, Philipp M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949793/ https://www.ncbi.nlm.nih.gov/pubmed/36844182 http://dx.doi.org/10.1097/HS9.0000000000000840 |
Ejemplares similares
-
Converging TLR9 and PI3Kgamma signaling induces sterile inflammation and organ damage
por: Lima, Braulio Henrique Freire, et al.
Publicado: (2019) -
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
por: Aydin, Ebru, et al.
Publicado: (2021) -
PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(l‐Glutamic Acid)‐Combretastatin A4 Conjugate in Metastatic Breast Cancer
por: Qin, Hanjiao, et al.
Publicado: (2019) -
Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in E-TCL1 mice
por: Hanna, Bola S., et al.
Publicado: (2020) -
Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
por: Zapatka, Marc, et al.
Publicado: (2021)